Expression level of BTN3A1 on the surface of CD14


Journal

Biochemical and biophysical research communications
ISSN: 1090-2104
Titre abrégé: Biochem Biophys Res Commun
Pays: United States
ID NLM: 0372516

Informations de publication

Date de publication:
15 01 2022
Historique:
received: 07 11 2021
accepted: 16 12 2021
pubmed: 25 12 2021
medline: 9 2 2022
entrez: 24 12 2021
Statut: ppublish

Résumé

Human γδ T cells expressing Vγ9Vδ2 T cell receptors exert a robust response to pathogens and malignant cells. These cells are activated by BTN3A1, which is expressed by pathogen-derived phosphoantigens (pAgs) or host-derived pAgs that accumulate in transformed cells or in cells exposed to aminobisphosphonates. Activated Vδ2 (+) T cells exert multiple effector functions; therefore, they are a promising candidate for immunotherapy. However, not all donors have γδ T cells with adequate proliferative activity. Here, we performed ex vivo culture of γδ T cells from 20 healthy donors and explored factors that may affect their expansion efficiency. Consistent with previous studies, we found that amplification of γδ T cells requires CD14

Identifiants

pubmed: 34952469
pii: S0006-291X(21)01695-8
doi: 10.1016/j.bbrc.2021.12.060
pii:
doi:

Substances chimiques

Antigens, CD 0
BTN3A1 protein, human 0
Butyrophilins 0
CD14 protein, human 0
Interleukin-2 Receptor alpha Subunit 0
Lipopolysaccharide Receptors 0
Receptors, Antigen, T-Cell, gamma-delta 0
Receptors, Fc 0
Zoledronic Acid 6XC1PAD3KF

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

47-54

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Mako Tomogane (M)

Department of Clinical and Translational Physiology, Kyoto Pharmaceutical University, 5 Nakauchi, Yamashina, Kyoto, Japan.

Maho Omura (M)

Department of Clinical and Translational Physiology, Kyoto Pharmaceutical University, 5 Nakauchi, Yamashina, Kyoto, Japan.

Yusuke Sano (Y)

Department of Clinical and Translational Physiology, Kyoto Pharmaceutical University, 5 Nakauchi, Yamashina, Kyoto, Japan.

Daiki Shimizu (D)

Department of Clinical and Translational Physiology, Kyoto Pharmaceutical University, 5 Nakauchi, Yamashina, Kyoto, Japan.

Yuki Toda (Y)

Department of Clinical and Translational Physiology, Kyoto Pharmaceutical University, 5 Nakauchi, Yamashina, Kyoto, Japan.

Shigekuni Hosogi (S)

Department of Clinical and Translational Physiology, Kyoto Pharmaceutical University, 5 Nakauchi, Yamashina, Kyoto, Japan.

Shinya Kimura (S)

Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Nabeshima 5-1-1, Saga, Japan.

Eishi Ashihara (E)

Department of Clinical and Translational Physiology, Kyoto Pharmaceutical University, 5 Nakauchi, Yamashina, Kyoto, Japan. Electronic address: ash@mb.kyoto-phu.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH